CDK4 and breast carcinoma: For example, the addition of CDK4/6 inhibitors to hormone deprivation therapy in HR + breast cancer, exploiting the CDK4/6 dependency of HR + breast cancer under hormone deprivation, is now the first-line treatment for advanced HR + breast cancer [143].